Federal Register / Vol. 66, No. 30 / Tuesday, February 13, 2001 / Notices 10029

soluble analogues of water-insoluble

drugs.

In particular, the present invention

describes novel analogues derived from

5-aminoflavone (TK2339) compounds.

These derivatives have shown good

differential activity in the NCI 60-cell

line in vitro cancer drug screen with

potent and selective cytotoxicity against

CAKI–1 and A498 renal, MCF–7 breast,

and OVCAR–5 ovarian carcinoma cell

lines. In addition, these derivatives have

shown in vivo activity against CAKI–1

and A498 renal carcinoma xenographs.

To overcome poor solubility of many

members of the flavone class of

compounds, a series of more

hydrophilic, polar conjugates were

prepared which are capable of forming

soluble salts. These novel compounds

display improved solubility in aqueous

solutions over the parent compound

without sacrificing potent antitumor

activity. Since these compounds possess

very favorable pharmaceutical

properties, they have the greater

potential to be useful in the treatment of

human cancers.

Dated: February 2, 2001.

Jack Spiegel,

Director, Division of Technology,

Development and Transfer, Office of

Technology Transfer, National Institutes of

Health.

[FR Doc. 01–3606 Filed 2–12–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Dental &

Craniofacial Research; Notice of

Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–33, Review of R13

Grants.

Date: February 16, 2001.

Time: 11 a.m. to 1 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Natcher Building,

Conference Room E1⁄2, Bethesda, MD 20892,

(Telephone Conference Call).

Contact Person: H. George Hausch, PhD,

Chief, 4500 Center Drive, Natcher Building,

Rm. 4AN44F, National Institutes of Health,

Bethesda, MD 20892, (301) 594–2372.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–34, Review of training

grants.

Date: February 21–22, 2001.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant

applications.

Place: The Hyatt Regency Hotel, 100

Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Yujing Liu, MD, PhD,

Scientific Review Administrator, National

Institute of Dental & Craniofacial Res., 45

Center Drive, Natcher Building, Rm. 4AN44F,

Bethesda, MD 20892, (301) 594–2372.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–24, Review of R13

Grants.

Date: February 28, 2001.

Time: 10 a.m. to 12 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: H. George Hausch, PhD,

Chief, 4500 Center Drive, Natcher Building,

Rm. 4AN44F, National Institutes of Health,

Bethesda, MD 20892, (301) 594–2372,

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–25, Review of R01s.

Date: April 5, 2001.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: Yasaman Shirazi, PhD,

Scientific Review Administrator, 4500 Center

Drive, Natcher Building, Rm. 4AN44F,

National Institute of Dental & Craniofacial

Res., Bethesda, MD 20892, (301) 594–2372.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–28, Review of R44

Grants.

Date: April 6, 2001.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD,

Scientific Review Administrator, 45 Center

Drive, Natcher Building, Rm. 4AN44F,

National Institutes of Health, Bethesda, MD

20892, (301) 594–2372.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–17, Review of R01

Grants.

Date: April 11, 2001.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD,

Scientific Review Administrator, 45 Center

Drive, Natcher Building, Rm. 4AN44F,

National Institutes of Health, Bethesda, MD

20892, (301) 594–2372.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel.

Date: April 24, 2001.

Time: 1 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD,

Scientific Review Administrator, 45 Center

Drive, Natcher Building, Rm. 4AN44F,

National Institutes of Health, Bethesda, MD

20892, (301) 594–2372.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.121, Oral Diseases and

Disorders Research, National Institutes of

Health, HHS)

Dated: February 6, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–3593 Filed 2–12–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Dental &

Craniofacial Research; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.